Home › Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
 

Keywords :   


Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

2015-07-01 08:07:56| drugdiscoveryonline Home Page

Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced the completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen on June 26, 2015

Tags: to treatment submission fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
More »